Aprogen Bio CB terms amended
에이프로젠
007460
Signal Score
Historical Avg Return (5d)
+0.61%
Data Coverage
100%n=2286
Risk-adjusted indicator based on 2286 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • CB Face Value: 50.8B KRW
- • Conversion Price: 3,778 KRW/Share
- • Shares from Conversion: 13,446,267 Shares
- • Max Dilution (new CB): 93.30% of current shares
- • Total Dilution (all CBs): 262.78% of current shares
- • Surface Interest Rate: 2%
- • Maturity Interest Rate: 4%
- • Maturity Date: June 23, 2029
- • Put Option First Exercise Date: December 23, 2027
- • Funds Purpose: 50.8B KRW for debt repayment
AI Analysis Summary
Aprogen Bio, a subsidiary of Aprogen, Inc., amended the terms for its 20th series private placement of convertible bonds (CBs) with a face value of 50.8 billion KRW. The maturity date, interest payment dates, principal repayment date, conversion request period, and put option exercise dates have all been extended by approximately 19 days. The CBs have a conversion price of 3,778 KRW per share, potentially issuing 13,446,267 new shares, representing a 93.30% dilution relative to the current outstanding shares. Including previously issued CBs, the total potential dilution reaches 262.78%. The funds are solely for debt repayment. The amendment itself is neutral, but the underlying CB issuance is highly dilutive, posing a significant negative impact on existing shareholder value.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.